Your Article Summary
See Latest ArticlesWhat measures relieve postherpetic neuralgia?
The Journal of Family Practice, 07/02/09
Garroway N et al. - Postherpetic neuralgia (PHN) is defined as pain lasting 1 to 3 months after resolution of acute herpes zoster (shingles) rash. It occurs in approximately 10% to 15% of patients and can cause significant morbidity. Tricyclic antidepressants, gabapentin, and pregabalin effectively reduce pain (strength of recommendation: A, at least 2 good-quality randomized controlled trials [RCTs] and/or meta-analyses). Opioids have demonstrated pain relief in 3 RCTs (SOR: A, consistent RCTs). Capsaicin and the lidocaine 5% patch relieve pain and decrease allodynia (SOR: B, recommendations from meta-analyses and lower-quality RCTs).
Related Articles
Tinnitus in postherpetic neuralgia
The Journal of Headache and Pain, 10/26/09
Relevance Score: 67%
Postherpetic Neuralgia: From Preclinical Models to the Clinic
Neurotherapeutics, 10/05/09
Relevance Score: 67%
The Effectiveness of Repetitive Paravertebral Injections with Local Anesthetics and Steroids for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster
Anesthesia & Analgesia, 10/21/09
Relevance Score: 66%
Treatment of Herpes Zoster and Postherpetic Neuralgia
Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 10/19/09
Relevance Score: 66%
Granulocyte colony-stimulating factor for recalcitrant postherpetic neuralgia: a prospective, open, pilot study in three patients
Clinical and Experimental Dermatology, 10/01/09
Relevance Score: 65%
Today in Neurology...keeping you current
Receive free subspecialty "5-minute updates" via email
What Do We Know About Chronic Tension-type Headache?
Discovery Medicine, 12/07/09
Simulated acupuncture and real acupuncture both reduced low back pain dysfunction and symptoms
Evidence-Based Medicine, 12/07/09
Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials
The Lancet, 12/07/09